BIIB

Biogen
D

BIIB

137.510
USD
2.52
(1.87%)
Market Open
Volume
33,802
EPS
14
Div Yield
-
P/E
13
Market Cap
20,152,176,495
OverviewSignalsIdeasNews
Related Instruments
ABBV
ABBV
1.650
(0.81%)
206.330 USD
AMGN
AMGN
5.73
(1.97%)
295.94 USD
GILD
GILD
-0.560
(-0.47%)
118.440 USD
INCY
INCY
0.540
(0.63%)
86.700 USD
JNJ
JNJ
1.810
(1.04%)
176.530 USD
LLY
LLY
18.32
(2.68%)
702.59 USD
MRK
MRK
1.630
(1.97%)
84.380 USD
PFE
PFE
0.085
(0.34%)
25.185 USD
REGN
REGN
8.20
(1.45%)
574.10 USD
More
News
Treasury Yields Decline as Market Anticipates Fed Rate Cuts

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

11 months ago
Economy News
Novo Nordisk Surges in Profit and Sales

Novo Nordisk Surges in Profit and Sales

1 year ago
Stocks News
More

Title: Biogen

Sector: Healthcare
Industry: Drug Manufacturers - General
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Trading. Social. Simple.
FacebookTwitterYoutube
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHelp Center
Social Network
The NetworkSignals NetworkIdeas NetworkBest TradersUser Reviews for Brokers
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.